News | August 30, 2010

Health Canada Approves RF Ablation System for Atrial Fibrillation


August 20, 2010 – Health Canada granted market approval for the Medtronic Ablation Frontiers Cardiac Ablation System, a radiofrequency (RF) ablation system to treat atrial fibrillation (AF).

The ablation tools now approved for use in Canada include the GENius Multi-Channel Radiofrequency Generator and the Pulmonary Vein Ablation Catheter (PVAC), a single anatomically shaped mapping and ablation catheter designed to efficiently isolate the pulmonary veins to treat AF. The GENius generator and PVAC, with the addition of the Multi-Array Septal Catheter (MASC) and Multi-Array Ablation Catheter (MAAC), are available in Europe and are under investigational use in the United States. Medtronic will provide periodic clinical updates on the safety and effectiveness of the PVAC catheter as a condition of Health Canada’s approval.

“This three-dimensional RF catheter is an improvement from the currently used focal system; it simplifies the AF ablation procedure allowing me to better predict my procedure times and therefore, treat more patients in one day,” said Yaariv Khaykin, M.D., electrophysiologist at the Southlake Regional Health Centre in Newmarket, Ontario, who was the first to use the new technology in Canada. “This novel technology also gives me the flexibility to tailor ablation therapy for specific patient needs and different anatomies.”

Catheter ablation is a common interventional treatment for many types of cardiac arrhythmias. When used to treat AF, RF catheter ablation is a minimally invasive procedure designed to stop the rapid beating of the atria by isolating and blocking the triggers and conduction pathways that can initiate AF. In Canada, AF ablation procedures traditionally use a point-by-point focal ablation technique involving multiple catheters. Medtronic’s novel three-dimensional catheter allows physicians to target a broader area and efficiently map, pace, ablate and confirm isolation of the pulmonary veins, with a single catheter.

Medtronic acquired U.S.-based Ablation Frontiers Inc., and Montreal-based CryoCath Technologies Inc. to form Medtronic’s AF Solutions division. When combined with Medtronic's existing electrophysiology (EP) systems product portfolio, AF Solutions offers an extensive line of diagnostic, cryoablation and radiofrequency ablation tools to diagnose and treat a broad spectrum of cardiac arrhythmias.

For more information: www.medtronic.com


Related Content

News

Sept. 8, 2026 — Abbot has announced that it has received U.S. Food and Drug Administration (FDA) approval for the ...

Home September 08, 2026
Home
News

Aug. 31, 2026 — At the European Society of Cardiology Congress in Munich, Abbott announced new late-breaking 12-month ...

Home September 02, 2026
Home
News

July 8, 2026 — Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) approved the Dual Energy ...

Home July 08, 2026
Home
News

May 21, 2026 — Adagio Medical Holdings, a provider of catheter ablation technologies for treating cardiac arrhythmias ...

Home May 22, 2026
Home
News

April 26, 2026 — New results from the multicenter catheter ablation versus anti-arrhythmic drugs for Ventricular ...

Home April 29, 2026
Home
News

April 24, 2026 — Johnson & Johnson recently announced the initiation of the PERSIGMA randomized controlled trial (RCT) ...

Home April 27, 2026
Home
News

April 26, 2026 – New results from the pivotal multicenter trial FULCRUM-VT show that ultra-low temperature ablation ...

Home April 27, 2026
Home
News

April 13, 2026 — Johnson & Johnson has announced favorable 12-month interim effectiveness and safety results from ...

Home April 13, 2026
Home
News

In a milestone for Broward Health in Ft. Lauderdale, Fla., Jose L. Baez-Escudero, M.D., chief of cardiology and ...

Home March 24, 2026
Home
News

Feb. 6, 2026 — Abbott has announced new clinical data from two late-breaking presentations at AF Symposium in Boston ...

Home February 06, 2026
Home
Subscribe Now